ClinicalTrials.gg
Active, not recruitingNCT06970847AMPLIFYUpdated May 14, 2026

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer

A Phase 3 interventional study of 64Cu-SAR-bisPSMA in Prostate Cancer, Prostate Cancer Patients With Detectable PSA Following Prostatectomy and Prostate Cancer Recurrent, sponsored by Clarity Pharmaceuticals Ltd. Active, not recruiting at 22 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Clarity Pharmaceuticals Ltd · Phase 3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
220
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,596 studies in Prostatic Neoplasms with a site in United States — 608 open to participants now, 975 under way, 101 of them phase 3. Prostatic Neoplasms · United States.

Planned enrollment
486th of 3,023
220 · median 48
Started
2025
with 160 others
Phase 3
284 of 3,596
42 open now
Primary completion
2026-12
later than 235 of 969 live
Registered
3,355th of 3,596
by date

Among the 3,596 studies in Prostatic Neoplasms with a site in United States, this one is the 486th largest by planned enrollment of the 3,023 interventional ones that give a count, is one of 161 that started in 2025, is one of 284 in phase 3, reaches primary completion later than 235 of the 969 other live ones, and was the 3,355th registered.

Prostatic Neoplasms

7,052 studies on the registry are indexed under Prostatic Neoplasms; 1,583 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

608 of the 3,596 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

603 more — sign in →

All 608 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,231 Prostatic Neoplasms studies recruiting now, 930 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,596 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The aim for this study is to investigate the ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer

03

Conditions studied

  • Prostate Cancer
  • Prostate Cancer Patients With Detectable PSA Following Prostatectomy
  • Prostate Cancer Recurrent
  • Prostate Cancer Patients Who Have Brachytherapy Seed Implant
  • Prostate Cancer Patients Treated by Radiotherapy
  • Cryotherapy

Browse trials for

Keywords

  • Prostate Cancer
  • Prostate
  • Biochemical Recurrence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years of age.
  2. Signed .
  3. ≥ 6 months as determined by the Investigator.
  4. confirmed adenocarcinoma of prostate per original diagnosis and completed subsequent definitive therapy.
  5. Participant potentially eligible for salvage therapy with curative intent (i.e. aligns with the definition of loco-regional therapy as described in protocol Section 7.2).
  6. PSA level after definitive therapy:

    1. Post-radical prostatectomy: Detectable or rising PSA that is ≥ 0.2 ng/mL with a confirmatory PSA ≥ 0.2 ng/mL (per AUA recommendation) or
    2. Post-radiation therapy, cryotherapy, or brachytherapy: Increase in PSA level that is elevated by ≥ 2 ng/mL above the nadir (per ASTRO-Phoenix consensus definition).
  7. Participant willing to undergo of a 64Cu-SAR-bisPSMA PET-positive lesion for histological confirmation of PC, where this is safe and feasible.
  8. An Eastern Cooperative Oncology performance status of 0-2.

Exclusion criteria

Exclusion Criteria:

  1. Participants who received agent within 5 biological half-lives prior to Day 1.
  2. Participants administered any high energy (>300 KeV) gamma-emitting radioisotope within 5 physical half-lives prior to Day 1.
  3. Participants with known predominant small cell or neuroendocrine PC.
  4. Previous systemic therapy for PC (with the exception of and adjuvant systemic therapy as part of the definitive therapy and/or salvage therapy with radiation).
  5. Ongoing treatment or treatment within 6 months of Day 1 with any systemic therapy (e.g. any investigational therapy, androgen-deprivation therapy, antiandrogen, gonadotropin-releasing hormone, luteinizing hormone-releasing hormone agonist or antagonist, chemotherapy, immunotherapy or radiotherapy) for PC.
  6. Participants for whom there is an intent to initiate a prohibited medication(s)/treatment(s) (refer to Section 7.3) during the course of the participant's involvement in the study.
  7. Known or expected to 64Cu-SAR-bisPSMA or any of its components.
  8. Any serious medical condition or extenuating circumstance (including receiving the investigational product or not capable of having a PET scan) which the investigator feels may interfere with the procedures or evaluations of the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    64Cu-SAR-bisPSMA 200MBq 64Cu-SAR-bisPSMA.

    Drug: 64Cu-SAR-bisPSMA

Interventions

  • All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA

06

What researchers measure

Primary outcomes

  1. Ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer

    Co-primary endpoints of participant-level CDR and region level PPV assessed independently for Day 1 and Day 2: * Participant-level CDR, defined as the proportion of TP participants scan out of all participants * Region-level PPV, defined as the proportion of TP regions out of all positive regions.

    Time frame: Up to 52 Weeks

Secondary outcomes

  1. To investigate the safety and tolerability of 64-CuSAR-bisPSMA

    Incidence and severity of TEAEs and SAEs following the administration of 64CuSARbisPSMA

    Time frame: Up to 52 Weeks

  2. To assess the participants-level PPV of 64Cu-SAR-bisPSMA PET/CT

    Participant-level PPV, defined as the proportion of participants with a TP scan out of all participants with a true or false positive scan.

    Time frame: Up to 52 Weeks

  3. To assess the participant-level DR of 64Cu-SAR-bisPSMA PET/CT

    Participant-level DR, defined as the proportion of participants with a positive scan out of all participants.

    Time frame: Up to 52 Weeks

  4. To determine the efficacy of 64Cu-SAR-bisPSMA PET/CT in participants with negative or equivocal conventional imaging at baseline

    Detection Rate in participants with a negative or equivocal conventional imaging at baseline.

    Time frame: Up to 52 Weeks

  5. To determine the effect of the composition of Reference Standard on the performance of 64Cu-SAR-bisPSMA PET/CT

    Positive Predictive Value (participant- and region-level) assessed in subgroups based on the type of evidence and with/without histopathology.

    Time frame: Up to 52 Weeks

  6. To evaluate the consistency among readers and the reproducibility of the 64Cu-SAR-bisPSMA PET/CT readings

    Inter-reader variability expressed with kappa statistics for the 64Cu-SAR-bisPSMA PET/CT interpretation by the three central readers.

    Time frame: Up to 52 Weeks

  7. To evaluate the consistency among readers and the reproducibility of the 64Cu-SAR-bisPSMA PET/CT readings

    Intra-reader variability expressed with kappa statistics for the 64Cu-SAR-bisPSMA PET/CT interpretation by the three central readers.

    Time frame: Up to 52 Weeks

  8. To determine the efficacy of 64Cu-SAR-bisPSMA PET/CT in participants with negative or equivocal conventional imaging at baseline

    Positive Predictive Values (participant and region level) in participants with a negative or equivocal conventional imaging at baseline.

    Time frame: Up to 52 Weeks

  9. To determine the effect of the composition of Reference Standard on the performance of 64Cu-SAR-bisPSMA PET/CT

    Correct Detection Rate assessed in subgroups based on the type of evidence and with/without histopathology.

    Time frame: Up to 52 Weeks

07

Study locations

22 sites
08

References and documents

Individual participant data

Plan to share: No — Concerns related to confidentiality.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's planned 19 months is below that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2025
First posted
May 14, 2025
StartActual
May 16, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06970847
Lead sponsor
Clarity Pharmaceuticals Ltd
Responsible party
Sponsor
First posted
May 14, 2025
Start date
May 16, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abefolastat tesaroxetan CU-64

Start the discussion